Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Sofosbuvir-based regimens were well tolerated and cure rates were high in this population.
The number of people treated for hepatitis C hit a low point during the COVID-19 pandemic.
People who received a shortened course of antiviral therapy were less likely to be cured.
The American College of Obstetricians and Gynecologists advises screening during each pregnancy.
With many hepatitis C treatments on the market today, patients may ask which hepatitis C treatment is right for me? What’s the difference?
The Supreme Court refused to hear Merck’s arguments on a hepatitis C patent, so the previous ruling in Gilead’s favor stands.
Rates of liver complications were similar, but HIV-positive people had more non-liver cancers and non-liver-related deaths.
In a recent British Columbia study, 1 in 10 people who began treatment were lost to follow-up.
The assurance arrives as the pharma giant cuts off most emergency access to remdesivir, a potential COVID-19 treatment.
Though low, this figure is three times the rate of discontinuation seen in clinical trials.
There are a variety of hepatitis C treatments offered for all genotypes, with various stages of liver damage.
Often people are reluctant to start using a hep C medication because they are concerned about the possible side effects during treatment.
Here is a fantastic story from Jonathan Nakamoto in the USA who treated and cured his hepatitis C with generic Harvoni from India in 2016.
There has been a lot of discussion about the side effects of Harvoni and other hepatitis C treatments with direct acting antivirals.
A U.S. appeals court upheld a judge’s previous decision to throw out a record-setting 2016 verdict in Merck’s favor.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.